机构:[1]The Research Center of Basic Integrative Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[2]Integrative Research Laboratory of Breast Cancer, Discipline of Integrated Chinese and Western Medicine, The second affiliated hospital of Guangzhou University of Chinese Medicine, Guangzhou,China广东省中医院[3]Tropical Medicine Institute, Guangzhou University of Chinese Medicine, Guangzhou, China
Chinese formulas have been paid increasing attention in cancer multidisciplinary therapy due to their multi-targets and multi-substances property. Here, we aim to investigate the anti-breast cancer and chemosensitizing function of Ai Du Qing (ADQ) formula made up of Hedyotis diffusa, Curcuma zedoaria (Christm.) Rosc., Astragalus membranaceus (Fisch.) Bunge, and Glycyrrhiza uralensis Fisch. Our findings revealed that ADO significantly inhibited cell proliferation in both parental and chemo-resistant breast cancer cells, but with little cytotoxcity effects on the normal cells. Besides, ADQ was found to facilitate the G2/M arresting and apoptosis induction effects of paclitaxel. Network pharmacology and bioinformatics analysis further demonstrated that ADQ yielded 132 candidate compounds and 297 potential targets, and shared 22 putative targets associating with breast cancer chemoresponse. Enrichment analysis and experimental validation demonstrated that ADQ might improve breast cancer chemosensitivity via inhibiting caveolin-1, which further triggered expression changes of cell cycle-related proteins p21/cyclinB1 and apoptosis-associated proteins PARP1, BAX and Bcl-2. Besides, ADQ enhanced in vivo paclitaxel chemosensitivity on breast cancer. Our study not only uncovers the novel function and mechanisms of ADQ in chemosensitizing breast cancer at least partly via targeting caveolin-1, but also sheds novel light in utilizing network pharmacology in Chinese Medicine research.
基金:
National Natural Science Foundation of China [81703764, 81573651, 81873306, 81703749]; Guangdong Science and Technology Department [2016A030306025]; Pearl River S&T Nova Program of Guangzhou [201506010098]; Combined Scientific Project - Guangdong Provincial Science and Technology Agency; Guangdong Provincial Academy of Traditional Chinese Medicine [2014A020221047]; Guangdong High-level University Construction Project [A1-AFD018161Z1510, A1-AFD018171Z11102, A1-AFD018171Z11101]; Guangdong High-level Personnel of Special Support Program [A1-3002-16-111-003]; Guangdong traditional Chinese medicine bureau project [20181132, 20182044]; Post-doctoral Science Foundation of ChinaChina Postdoctoral Science Foundation [2017M612644, 2017M622669, 2018T110861]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2017A030310213]; Guangdong provincial key project [2016kzdxm032]; Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine [YN2018MJ07, YN2018QJ08]
第一作者机构:[1]The Research Center of Basic Integrative Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China
通讯作者:
通讯机构:[1]The Research Center of Basic Integrative Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China[2]Integrative Research Laboratory of Breast Cancer, Discipline of Integrated Chinese and Western Medicine, The second affiliated hospital of Guangzhou University of Chinese Medicine, Guangzhou,China
推荐引用方式(GB/T 7714):
Wang Neng,Yang Bowen,Zhang Xiaotong,et al.Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer[J].FRONTIERS IN PHARMACOLOGY.2018,9:doi:10.3389/fphar.2018.01106.
APA:
Wang, Neng,Yang, Bowen,Zhang, Xiaotong,Wang, Shengqi,Zheng, Yifeng...&Wang, Zhiyu.(2018).Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer.FRONTIERS IN PHARMACOLOGY,9,
MLA:
Wang, Neng,et al."Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer".FRONTIERS IN PHARMACOLOGY 9.(2018)